长效奥曲肽影响大鼠肝纤维化形成的研究  

Observation of the effects of long-acting octreotide (sandostatin LAR) on hepatic gibrosis in rats

作　　者：杨文燕[1] 吴建新[2] 戴强[1] 江佛湖[1] 赵力民[1] 张燕捷[1] 朱黎明[1] 王碧君[1] 

机构地区：[1]上海交通大学医学院附属第三人民医院消化内科,上海201900 [2]上海交通大学医学院附属新华医院消化内科,上海201900

出　　处：《中国医药导报》2007年第09Z期17-19,共3页China Medical Herald

摘　　要：目的:观察和探讨长效奥曲肽对四氯化碳(CCl4)诱发的大鼠肝纤维化的影响及机制。方法:SD大鼠40只,随机分为正常对照组(n=8)、肝纤维化组(n=16)、长效奥曲肽组(n=16)。通过40%CCl4皮下注射(3ml/kg)诱导建立大鼠肝纤维化模型,长效奥曲肽组同时给与长效奥曲肽(善龙,0.8mg/kg)肌肉注射,每28天给药1次。8周后观察大鼠肝脏大体形态、肝脏重量/体重比和组织学改变;用酶联免疫吸附法(ELISA)测定血清透明质酸(HA)、Ⅲ型前胶原N端肽(PⅢNP)含量。结果:正常对照组大鼠肝脏大体形态和组织学无异常改变。肝纤维化组及长效奥曲肽组大鼠肝脏质地变硬,表面明显结节,组织学见肝细胞脂肪变性、坏死、纤维组织增生,假小叶形成等,但后者组织学损害显著轻于前者(P<0.05)。肝纤维化组及长效奥曲肽组肝脏重量/体重比均明显高于正常对照组(P<0.01),但长效奥曲肽组低于肝纤维化组(P<0.05)。正常对照组大鼠血清HA、PⅢNP含量分别为(18.5±3.8)ng/ml、(8.2±3.4)ng/ml,肝纤维化组大鼠血清HA、PⅢNP含量分别为(179.3±33.5)ng/ml,(59.6±15.6)ng/ml。高于正常对照组(P<0.01)。长效奥曲肽组大鼠血清HA、PⅢNP含量分别为(152.4±36.1)ng/ml,(41.2±13.4)ng/ml,显著高于正常对照组(P<0.01),但低于肝纤维化组(HAP<0.05;PⅢNPP<0.01)。结论:长效奥曲肽能减缓大鼠肝纤维化形成。Objective： To observe the effect of long acting release octreotide （sandostatin LAR） on hepatic fibrosis in rats by CCl4. Methods： Forty SD rats were assigned randomly into 3 groups, i.e. normal control group （n=8）, hepatic fibrosis group （n=16） and long acting octreotide group （n=16）. Apart from normal control group, the rats in other two groups were subcutaneously injected with 40%CCl4 （3 ml/kg）for induction of hepatic fibrosis. The rats in the long acting octreotide group were treated additionally with long acting octreotide （0.8 mg/kg） intramuscular/y once per 28 days. After 8 weeks, observed macroscopic features of the liver, measured weight ratio of liver to body, and the serum hyaluronic acid （HA）, aminotermihal propeptide of type Ⅲ procollagen （P Ⅲ NP） were detected with ELISA. Results： There was neither macroscopic nor microscopic abnormalities demonstrated in the liver in normal control group. However, in the latter two groups, the liver got hard, blunting and nodosity-like, but significantly lessened juries, including fatty degeneration and necrosis, fibroplasias, deformed structures and formation of pseudo-lobule, shown in long acting octreotide group, compared with hepatic fibrosis group. The ratio of liver to bodyweight was higher in hepatic fibrosis group than in long acting octreotide group （P〈0.05）, and the weight ratios of liver to body in both groups were significantly higher than in normal control group （P〈0.01）The serum HA and P IU NP in normal control group were （18.5±3.8） ng/ml, （8.2±3.4） ng/ml ,respectively,the serum HA and P IU NP in hepatic fibrosis group were （179.3±33.5） ng/ml,（59.6±15.6）ng/ml, and （152.4±36.1） ng/ml and （41.2±13.4）ng/ml respectively in long acting octreotide group, both significantly higher than in the controls （P〈0.01）： However, the parameters detected in long acting octreotide group were significantly lower than in hepatic fibrosis group（HA P〈0.05 ;PⅢNP P〈0.01 ）. Co

关 键 词：长效奥曲肽 肝纤维化 透明质酸 Ⅲ型前胶原N端肽 

分 类 号：R542.23[医药卫生—心血管疾病]